What does Rock Springs Capital invest in?
Rock Springs Capital invests most often at Series B and Series C (74% of the rounds on record), in sectors such as Healthcare.

United States · Investor
Last cheque observed Jun 2026; 36 cheques on record.
Deploying nowNew fund $1.1B, Jan 2026Hedge fund
Follow Rock Springs Capital and see its new cheques in your feed.Start following
1 cheques in the last 12 months
Mostly Series B and Series C: 74% of its rounds
1 exits from the portfolio
Rock Springs Capital is a specialist healthcare investment firm managing $1.8B across two strategies.From their own website
Every round we can evidence, newest first36 appearances
1 round
2 rounds
1 round
2 rounds
1 round
1 round
1 round
15 rounds
10 rounds
1 round
1 round
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
Named by the firm itself, on a filing, its Form ADV or its company registration5 named
We also hold 12 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
From the firm's own filings with the SEC, which it must file accurately by law
Funds on its Form ADV
2 private funds, $5.8B in gross assets · filed Mar 2024
Companies it backed that were later bought or listed1 in all
An exit counts when it came after the firm's first round in the company. From historical deal records.
The investors most often in the same rounds as Rock Springs Capital. A count of rooms they were both in, not a relationship either has claimed.
The latest companies Rock Springs Capital put money into.
Rock Springs Capital invests most often at Series B and Series C (74% of the rounds on record), in sectors such as Healthcare.
36 investments on record, 1 of them in the last 12 months. The most recent was in Jun 2026.
Its most recent investments on record: City Therapeutics (Series B, Jun 2026), Zenas BioPharma (Series C, May 2024) and Apollo Therapeutics (Series C, Jan 2024).
The median round it joins is $102M.
Rarely, if at all: none of its 36 investments on record names it as the lead.
Most of the companies it backs are in the United States (78%) and the United Kingdom (8%).
Yes: it is actively investing, with 1 investments in the last 12 months.
Most often RA Capital Management (13 rounds together), New Enterprise Associates (11 rounds together) and OrbiMed (9 rounds together).
Find the investors who back rounds like yours, and keep every conversation on one fundraising board.
Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it